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Abstract
In vivo 1H magnetic resonance spectroscopy (1H-MRS) investigations of amyotrophic lateral sclerosis (ALS) mouse brain
may provide neurochemical profiles and alterations in association with ALS disease progression. We aimed to longitu-
dinally follow neurochemical evolutions of striatum, brainstem and motor cortex of mice transgenic for G93A mutant
human superoxide dismutase type-1 (G93A-SOD1), an ALS model. Region-specific neurochemical alterations were
detected in asymptomatic G93A-SOD1 mice, particularly in lactate (19%) and glutamate (þ8%) of brainstem, along
with g-amino-butyric acid (30%), N-acetyl-aspartate (5%) and ascorbate (þ51%) of motor cortex. With disease
progression towards the end-stage, increased numbers of metabolic changes of G93A-SOD1 mice were observed (e.g.
glutamine levels increased in the brainstem (>þ66%) and motor cortex (>þ54%)). Through ALS disease progression, an
overall increase of glutamine/glutamate in G93A-SOD1 mice was observed in the striatum (p< 0.01) and even more so
in two motor neuron enriched regions, the brainstem and motor cortex (p< 0.0001). These 1H-MRS data underscore a
pattern of neurochemical alterations that are specific to brain regions and to disease stages of the G93A-SOD1 mouse
model. These neurochemical changes may contribute to early diagnosis and disease monitoring in ALS patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease that leads to speciﬁc degeneration of
motor neurons originating in the central nervous
system (e.g. spinal cord, brainstem and motor cortex).
ALS patients simultaneously suﬀer from progressive
paralysis of skeletal muscles. ALS diagnosis currently
relies on clinical assessment and compatible electro-
physiological ﬁndings, whereas imaging is mostly used
to exclude other pathologies. However, the aetiology of
ALS in motor neurons, particularly in upper motor
neurons, remains variable.1–3 A crucial advantage of
animal studies is the opportunity to follow animals
before symptom onset and throughout the disease pro-
gression. Therefore, in vivo characterization of the aeti-
ology (e.g. brain metabolism) in the most consistent
murine model of ALS is particularly important for
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early diagnosis and follow-up of therapeutic inter-
ventions in animal models. Remarkably, mice that
ubiquitously overexpress mutant human superoxide
dismutase 1 (hSOD1) develop an adult-onset hind
limb paralysis that closely mimics human disease
ALS.4–6 Consequently, mice transgenic for G93A
mutant hSOD1 (G93A-SOD1 mice) became widely
used as the model for ALS and have been characterized
for their neuropathology.7,8 Therefore, longitudinally
studying metabolism of brain regions with abundant
motor neurons in the G93A-SOD1 mouse model
could provide neurochemical alterations associated
with disease progression and hint towards a metabolic
signature of motor neuron degeneration that may help
the early diagnosis, evaluation of therapeutic treat-
ments and follow-up of ALS patients.
Recently, magnetic resonance techniques, such as
imaging (MRI) and spectroscopy (MRS), have proven
to be powerful investigation tools for non-invasive
studies in ALS patients.9 For instance, in addition
to the aforementioned ALS diagnosis purpose for
ALS patients, MRI techniques have shown promising
results in detection of abnormal T2-hyperintensities in
central nervous regions only with abundant lower
motor neurons (i.e. spinal cord and brainstem of
G93A-SOD1 mice).10,11 Unlike MRI, which provides
anatomical and structural contrasts, 1H-MRS has
been used to evaluate brain metabolism (e.g. highly
abundant metabolites of the primary motor cortex
and brainstem of ALS patients) and metabolic alter-
ations speciﬁc to motor neurons.12–20 However, except
some in vitro spectroscopy analyses of murine ALS
models,10,21 in vivo 1H MRS studies of the ALS mice
remains limited. Therefore, the aim of this study was
to longitudinally follow neurochemical proﬁle evolu-
tions of the striatum, motor cortex and brainstem in
a transgenic G93A-SOD1 mouse model with well-
characterized neuropathology7 to provide plausible
changes and to seek potential ALS biomarkers speciﬁc
to motor neurons.
Materials and methods
Animals
All animal experiments were approved by the
Veterinary Oﬃce of Canton de Vaud, and were con-
ducted according to the federal and local ethical guide-
lines, EXPANIM (Expe´rience sur animaux- SCAV,
Service de la consommation et des aﬀaires ve´te´rinaires,
Switzerland) and in compliance with ARRIVE
guidelines (Animal Research: Reporting in Vivo
Experiments) for how to REPORT animal experiments.
Transgenic mice overexpressing G93A human SOD1
(B6SJL-Tg(SOD1G93A)1Gur/J) were originally
obtained from the Jackson Laboratory (Bar Harbor,
Maine, USA). This line was thereafter maintained by
breeding G93A males with wild-type (WT) females
(B6SJL/F1, L’Arbresle, France). The oﬀspring were
genotyped by PCR ampliﬁcation of DNA extracted
from the ear tissue as described previously.22
Thereafter, all mice were collectively housed (maximum
ﬁve individuals per MICE cage, surface area 528 cm2,
with standard beddings) on a 12-h light/dark cycle
(lights on at 7 a.m.) and fed with a standard chow
(Diet 2918, Provimi Kliba AG) in speciﬁc pathogen-
free facility. Thirteen male G93A-SOD1 mice were
obtained along with their 14 WT cohorts for this
study. The mean lifespan of the transgenic animals
was approximately 125 days, identical to an ALS
mouse model with well-documented neuropathology.7
Based on visible motor abnormality, e.g. hind limb
splay,7,23 and preliminary electromyographical meas-
urements and swimming ability (data not shown),8
postnatal day 60 (P60) as an asymptomatic stage and
disease onset at 90 days of age were found in our trans-
genic mice, similar to the aforementioned ALS mouse
model.7 Therefore, with the aim to detect potential
biomarkers relating to diagnosis and prognosis, the
mice were studied at asymptomatic (P60), at a mildly
post-symptomatic stage (P100), at an advanced symp-
tomatic stage (P115) and at an end stage close to mori-
bund (P120-122, simpliﬁed as P122).7
In order to reduce any potential eﬀects of repetitive
measurements on mice under isoﬂurane, animals were
studied in a random manner. In each group, we typic-
ally measured more than seven mice (n 7), which was
reached for this study except for transgenic mice at
advanced symptomatic stage (n¼ 6 at P115 for both
striatum and motor cortex, and n¼ 5 for brainstem).
In late stage animals (P120–122), only four out
of seven transgenic animals could be measured by
1H-MRS, because of the death of some mice before
the measurement could be performed.
For MR studies, anaesthesia was induced under 3%
isoﬂurane mixed with air and oxygen (2:1). Isoﬂurane
ﬂow rate was then reduced to 2% for further proced-
ures. The animals were then ﬁxed in a stereotaxic
holder (RAPID Biomedical GmbH, Rimpar,
Germany) with two earpieces and a bite bar. Rectal
temperature and respiratory rates of animals were rec-
orded using an MR-compatible system (Model 1025,
SA Instruments Inc., NY, USA). The isoﬂurane ﬂow
concentration was continuously adjusted in the range
of 0.8–2% to maintain physiological conditions (i.e. the
respiratory rates of animals in the range of 90–120
breaths per minute). The rectal temperatures of animals
were kept at 35–37C by circulating warm water.
The entire period of MR study was in the range of
1.5–2 h for each mouse. Immediately after all MR
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measurements, 15 mL of tail bleeds were recovered and
diluted in 15 mL of Dulbecco’s phosphate-buﬀered
saline (Sigma-Aldrich Inc., USA). Glucose and lactate
contents of the diluted samples were immediately mea-
sured using two nearby pre-calibrated analysers (GM7
Micro-Stat, Analox Instruments Inc., UK).
MR instruments
All MR studies were carried out in a horizontal 9.4
Tesla (T) magnet (26 cm-inner-diameter, Magnex,
UK) with a 12-cm-diameter gradient (400mT/m,
200 ms). The magnet was interfaced to a DirectDrive
console (Vnmrj, Agilent Inc., USA). B0 drift was less
than 10Hz and eddy currents were minimized within
0.01%.24 A homemade quadrature 1H radiofrequency
(RF) coil with two geometrically decoupled 12-mm-
diameter loops resonating at 400MHz was used for
transmitting and receiving RF.
Anatomical MRI and localised 1H MRS
Fastest spin echo (FSE) imaging was applied to acquire
multi-slice anatomical images with the following par-
ameters: a 20 20mm2 ﬁeld of view (FOV) with a
256 256 matrix, 20 0.6mm slices, 8 echo train
lengths, 50ms eﬀective echo time (TEeﬀ), repetition
time (TR)¼ 5000ms and 4 averages. Such imaging par-
ameters result in T2-weigted images that allow identify-
ing abnormal T2 hyper-intensities.
25
Local ﬁeld homogeneities were optimised for each
examined brain region using FASTMAP26 without
exceeding the maximum strength of both ﬁrst and
second-order shim gradients, as previously described.27
The resulting spectral linewidths (FWHMs) of unsup-
pressed water signals were in the range of 11–18Hz.
Localised 1H-MRS was applied using SPECIAL (SPin
ECho, full Intensity Acquired Localized, TE/TR¼ 2.8/
4000ms)28 on two brain regions with abundant motor
neurons (i.e. motor cortex and brainstem). A control
brain region was selected (e.g. striatum). To obtain suf-
ﬁcient signal-to-noise ratios (e.g. SNRs 10) for fur-
ther quantiﬁcation, 160–320 averages were used.
LCModel29 was applied to quantify the 1H-MR
spectra, which had been carefully processed (i.e.
frequency drift corrected and summed).25 The unsup-
pressed water signals from the identical regions of inter-
ests (ROIs) were used as internal references for absolute
concentrations. Water contents of mouse cortex
(77 1%) and striatum (78 3%) measured in our
preliminary results were similar to other studies.30
However, the water content of mouse brainstem, mea-
sured at 73 0% was signiﬁcantly lower. Therefore,
73% water content (40mol/L) was used for the brain-
stem, whereas 80% water content (44mol/L) was used
for the cortex and striatum to be consistent with previ-
ous studies.25,31–33 Since T1 reﬂects brain water content
linearly34 and changed minimally in ALS mice with dis-
ease progression,11 water contents were assumed to not
vary during the entire period of MR experiment.
In this study, all metabolites except macromolecules
(Mac) in the basic set of the LCModel were simulated,
i.e. alanine (Ala), ascorbate (Asc), aspartate (Asp),
b-hydroxybutyrate, creatine (Cr), myo-inositol (myo-
Ins), g-aminobutyric acid (GABA), glucose (Glc),
glutamine (Gln), glutamate (Glu), glycine (Gly), glycer-
ophosphocholine (GPC), glutathione (GSH), lactate
(Lac), N-acetyl-aspartate (NAA), N-acetyl-aspartyl-
glutamate (NAAG), phosphocholine (PCho),
phosphocreatine (PCr), phosphorylethanolamine (PE),
scyllo-inositol, and taurine (Tau). In general, metabol-
ites with Crame´r–Rao bounds (CRLBs)> 50% were
considered not detectable.27,31 For instance, Tkac
et al.31 reported that suﬃcient signal-to-noise ratios
(i.e. SNR> 10) and quality spectral data at 9.4 T
oﬀered CRLBs 30% among most metabolites,
except Ala, Asp, GSH, NAAG and PE.31 Since GPC
and PCho were strongly correlated in the LCModel
analysis (jrj  0.8) due to the very similar spectral res-
onances, the sum of GPC and PCho (GPCþPCho)
was reported. In our preliminary results, scyllo-inositol
and b-hydroxybutyrate were noticeably with
CRLBs> 50% over several brain regions and therefore
not reported. Some metabolites show regional variation
in concentration18,22 e.g. Ala, Asp Glc, Gly and NAAG
etc., CRLB variations are also anticipated.
Statistics
Statistical tests were carried mainly in GraphPad
(STATCON, Witzenhausen, Germany). Initially,
unpaired student t-test was applied. To further evaluate
genotype and age factors, two-way ANOVA was
applied. Values were shown as mean standard errors
of means (SEMs) unless speciﬁed and a signiﬁcant level
was reached when p-value was 0.05. Since the partial
least squares discriminant analysis (PLS-DA) has been
shown capable of analysing a large number of metab-
olites to identify potential biomarkers,35 a similar
approach was used to evaluate our data at an early
stage of the disease (P60, asymptomatic).36,37
Results
Regional 1H-MR spectra and neurochemical profiles
of wild-type mouse striatum, motor cortex and
brainstem were distinct
Initially, we acquired multi-slice FSE images with the
desired spatial resolution, depicting ﬁne anatomical
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structures of mouse brain (Figure 1(a)). The quality
images allowed for precise localisation of three investi-
gated brain regions – striatum, motor cortex and brain-
stem – for further 1H-MRS studies. After adjustments
of local ﬁeld homogeneities, the resulting metabolic
linewidths of volumes of interests (i.e. striatum, motor
cortex and brainstem) were 7 1Hz, 10 1Hz and
13 2Hz, respectively. The combination of satisfactory
water suppression and suﬃcient scans (160–320, as in
methods) led to the suﬃcient spectral SNRs to be
14 2, 14 3 and 16 2, respectively.
From the obtained 1H-MR spectra (Figure 1(a)),
striking spectral characteristics of three examined
brain regions were apparent. For instance, a typical
1H-MR spectrum of mouse motor cortex revealed
lower Tau, Ala and Lac signals but higher NAA and
Figure 1. Typical MR images and spectra (a) of one wild-type (WT) mouse, and quantified regional neurochemical profiles (b) of
striatum (grey, n¼ 7), motor cortex (white, n¼ 9) and brainstem (solid black, n¼ 7). Both transverse and sagittal images were
acquired to locate the volume of interests (VOIs), such as striatum (1.5 2 1.8 mm3), motor cortex (2 1 1.5 mm3) and brain-
stem (3.5 1.5 2.5 mm3). MR spectra were from specific regions were shown in the right most side. All spectra were processed to
have similar metabolic linewidths and scaled to the intensities of total creatine (Crþ PCr) and macromolecule (Mac). Panel b illustrates
spectral quantification and further two-way ANOVA analysis followed by the Bonferroni post-tests. ‘‘*’’ indicates difference between
brainstem and striatum. ‘‘&’’ indicates difference between motor cortex and striatum. The increased number of symbols indicates
p¼ 0.05, 0.01 and 0.001.
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Glu signals when compared to the striatum. In add-
ition, lower Ala, Tau and Glu but higher Gly, NAA
and Lac spectral signal intensities were consistently
observed in the 1H-MR spectra of mouse brainstem
(Figure 1(a)) when comparing to both motor cortex
and striatum. As depicted in Figure 1(b), a total of 19
metabolites were reliably quantiﬁed (CRLBs in
Supplemental Table 1) in each brain region, showing
region-speciﬁc characteristics.
1H-MRS revealed metabolic changes in the brain
of asymptomatic G93A-SOD1 mice
In the absence of apparent T2-hyperintensity enhance-
ment, we next focused on spectral analysis of speciﬁc
metabolites in all investigated brain regions, comparing
the ALS G93A-SOD1 mice with their WT counter-
parts. Based on both symptom and lifespan of the
G93A-SOD1 mice, four diﬀerent ages, including P60
(asymptomatic), P100 (mild symptomatic), P115
(advanced symptomatic stage) and P122 (end-stage),
were studied and analysed.
In the asymptomatic G93A-SOD1 animals,
1H-MRS data identiﬁed some neurochemical changes
mainly in the motor cortex (Table 1, unpaired student
t-test). Notably, increased Asc (2.3 0.2 vs. 1.5
0.2 mmol/g) and decreased GABA (1.2 0.1 vs.
1.7 0.1 mmol/g) and NAA (8.0 0.2 vs. 8.4
0.2 mmol/g) signals were apparent in the symptomatic
G93A-SOD1 mice when compared to their WT con-
trols. In addition, some statistically signiﬁcant meta-
bolic changes were also observed in G93A-SOD1
mouse striatum (e.g. a 13% increase in Glu, 8.6 0.3
vs. 7.6 0.2 mmol/g, G93A-SOD1 vs. WT, respectively)
and brainstem (an 8% increase in Glu, 5.8 0.8 vs.
5.4 0.1 mmol/g; and a 19% reduction in Lac,
6.4 0.5 vs. 5.2 0.2 mmol/g). However, body weight,
blood glucose and lactate levels of those G93A-SOD1
mice did not diﬀer from their controls, as summarised
in Table 2.
Neurochemical profiles were modified in the brain of
symptomatic G93A-SOD1 mice
The non-invasive characteristics of 1H-MRS allow
studying G93A-SOD1 mice with disease progression.
The G93A-SOD1 mice presented mild motor dysfunc-
tion that reﬂected symptoms of ALS patients at the
time when they ﬁrst sought medical advice (i.e. P100
and 1H-MRS data at this time point revealed spectral
modiﬁcations in the G93A-SOD1 mice that were dis-
tinct from those observed at P60 (Table 1, unpaired
student t-test)). While glucose and lactate levels in
blood did not diﬀer between the two groups despite a
decrease trend in body weights in G93A-SOD1 mice
(Table 2, two-way ANOVA), a prominent decrease in
Lac was noticeable in all three examined brain regions
of G93A-SOD1 mice (Table 1). In G93A-SOD1 mice,
increases in Gln were observed in the brainstem
(þ 28%, 2.9 0.1 vs. 2.3 0.1mmol/g, G93A-SOD1
vs. WT) and in the motor cortex (þ22%, 3.0 0.1 vs.
2.4 0.2 mmol/g), while decreases in both Glu (12%,
9.9 0.2 vs. 11.3 0.2mmol/g) and myo-Ins (14%,
3.5 0.2 vs. 4.1 0.2 mmol/g) occurred in the motor
cortex (Table 1).
When at P115, the G93A-SOD1 mice presented
strong motor dysfunction similar to the advanced
stages of ALS. There were increased numbers of neuro-
chemical changes at this advanced stage, in particular
in the brainstem and motor cortex (where motor neu-
rons are mainly located). More speciﬁcally, increases in
Gln, Gln/Glu, myo-Ins and the sum of creatine and
phosphocreatine (CrþPCr), and decreases in Lac and
GABA were observed in the brainstem of transgenic
mice (Table 1). Increases in Gln and Gln/Glu, and
reductions in Ala, Lac, Glu, GPC and GABA were
detected in the motor cortex of G93A-SOD1 mice
(Table 1). When compared to their mild symptomatic
stage (i.e. at P100), most changes in both regions of
G93A-SOD1 mice were preserved except Asp in the
brainstem and myo-Ins in the motor cortex. Yet, even
at this advanced stage, we consistently observed reduc-
tions in both Ala and Lac in the striatum of
G93A-SOD1 mice (Table 1).
At P122, G93A-SOD1 mice became symptomatic
with hind limb paralysis. At this stage, most neuro-
chemical changes in G93A-SOD1 mice at P115 per-
sisted. Highly elevated Gln and reduced Lac levels
were consistently observed in all three brain regions
(Table 1). Furthermore, Glc in both the motor cortex
and brainstem was substantially elevated, while both
blood glucose and lactate levels were not diﬀerent
from their WT cohorts (Tables 1 and 2).
Neurochemical profile evolved in specific brain region
In addition to genotype, we further analysed the
most relevant time-dependent metabolic changes of
G93A-SOD1 and WT mice. Less time-dependent vari-
ations were observed in WT mice compared to their
G93A-SOD1 counterparts (Figures 2 to 4). Among all
investigated brain regions, the striatum exhibited lim-
ited age-dependent metabolites when compared to
motor cortex and brainstem, two brain regions with
abundant motor neurons (Supplementary Table 2).
The metabolites associated with excitatory neuro-
transmission, Gln and Glu in the G93A-SOD1 mice,
evolved diﬀerently from their controls (Figure 2).
For instance, a general trend toward an increase in
Gln (Figure 2(a)) and a trend toward a decrease in
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Table 1. Summary of metabolic changes observed in the brainstem, motor cortex and striatum of G93A-
SOD1 mice and their countertypes at P60, P100, P115 and a very late stage (P120–122, simplified as P122).
Age and structure
Relative increase compared
to controls (%, p-value)
Relative decrease compared
to controls (%, p-value)
P60
Brainstem Glu (þ8%, 0.02) Lac (19%, 0.04)
Glx (þ7%, 0.04)
Motor cortex Asc (þ51%, 0.02) GABA (30%, 0.003)
NAA (5%, 0.04)
Glu (4%, 0.052)a
Striatum Glu (þ13%, 0.02)
Glx (þ14%, 0.02)
P100
Brainstem Gln (þ28%, 0.0005) Lac (21%, 0.04)
Glx (þ16%, 0.003)
Asp (þ52%, 0.03) Ala (45%, 0.02)
PCr (þ23%, 0.02)
Cr þ PCr (þ16%, 0.0007)
Motor cortex Gln (þ22%, 0.02) Glu (12%, 0.0004)
Glx (6%, 0.04)
Gln/Glu (þ40%, 0.002) Lac (61%, 0.002)
Ala (45%, 0.005)
myo-Ins (14%, 0.003)
Striatum PCr (þ22%, 0.006) Cr (11%, 0.004)
Lac (44%, 0.03)
P115
Brainstem Gln (þ36%, 0.009) GABA (15%, 0.056)a
Gln/Glu (þ38%, 0.058)a Lac (23%, 0.03)
myo-Ins (þ42%, 0.0002)
Cr þ PCr (þ15%, 0.005)
Tau (þ25%, 0.02)
Motor cortex Gln (þ33%, 0.04) Ala (61, 0.02)
Gln/Glu (þ56%, 0.02) Lac (58%, 0.04)
Glu (13%, 0.006)
GPC (44%, 0.02)
GABA (20%, 0.03)
Striatum Glc (þ66%, 0.066)a Ala (30%, 0.02)
Lac (54%, 0.03)
P122
Brainstem Gln (þ66%, 0.001)
Gln/Glu (þ103%, 0.008) Lac (41%, 0.02)
myo-Ins (þ38%, 0.063)a
Cr þ PCr (þ16%, 0.003)
Cr(þ21%, 0.03)
Motor cortex Gln (þ54%, 0.001) Ala (83%, 0.022)
Gln/Glu (þ122%, 0.061)a Lac (84%, 0.011)
Glc(þ264%, 0.006) Glu (28%, 0.032)
GluþGln (12%, 0.063)a
Striatum Gln (þ42%,< 0.0001)
Tau (þ12%, 0.03) Ala (45%, 0.03)
Glc (þ69%, 0.02) Lac (76%, 0.02)
Note: p-value was evaluated using unpaired student t-test.
aIndicates a statistically different trend.
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Glu (Figure 2(b)) were observed in all three brain
regions. Despite that, Glu in the striatum and brain-
stem of SOD1 mice was slightly higher at P60 than Glu
at P100 and were close to normal at P115 when com-
pared to age-matched WT controls. Consequently, Gln/
Glu ratios increased for all time-points in the motor
cortex (genotype factor p< 0.0001, two-way ANOVA,
Supplementary Table 2), only after mild symptoms in
the brainstem (genotype factor p< 0.0001) and at end-
stage in the striatum (genotype factor p< 0.01), of
G93A-SOD1 mice versus WT mice. In addition, the
sums of Glu and Gln (GluþGln, Glx) in the motor
cortex of SOD1 mice at all time-points were consist-
ently lower than WT controls, while Glx levels in the
striatum (genotype factor p< 0.01) and brainstem
(genotype factor p< 0.0001) of G93A-SOD1 mice
were above normal levels (Figure 2(e)).
GABA, one inhibitory neurotransmitter, was con-
sistently lower in G93A-SOD1 animals than in WT
mice. This observation reached statistical signiﬁcance
in the striatum (genotype factor p< 0.01, two-way
ANOVA, Figure 2(c), Supplementary Table 2), motor
cortex (genotype factor p< 0.01) and brainstem (geno-
type factor p< 0.001) between G93A-SOD1 mice and
their controls. Gly, another inhibitory neurotransmit-
ter, was however noticeably higher in the brainstem of
G93A-SOD1 mice when compared to WT animals
(genotype factor p< 0.05, Figure 2(d)).
Time-dependent changes in metabolites linked to
energy metabolism were also assessed. Hence, Lac
levels remained lowered in all three investigated brain
regions of G93A-SOD1 mice throughout disease pro-
gression (genotype factor p< 0.0001, two-way
ANOVA, Figure 3, Supplementary Table 2), while
blood lactate levels were found only to be age-depen-
dent in G93A-SOD1 mice (age factor p< 0.05, Table 2).
CrþPCr tended to increase in the motor cortex (age
factor p< 0.05, Figure 3(d), Supplementary Table 2)
and brainstem (genotype factor p< 0.001 and age fac-
tor< 0.05) of G93A-SOD1 mice. PCr/Cr ratio was
slightly elevated in the striatum of G93A-SOD1 mice
(genotype factor p< 0.05). In the contrary, a statistic-
ally signiﬁcant reduction of PCr/Cr was seen in the
motor cortex of transgenic animals (age factor
p< 0.05).
Myo-Ins, a putative glial marker, was highly ele-
vated in the brainstem (genotype factor p< 0.0001,
two-way ANOVA, Figure 4(a), Supplementary Table
2) but became lowered in the striatum (genotype
factor p< 0.05) and motor cortex (genotype factor
p< 0.01) of G93A-SOD1 mice. NAA, a potential neur-
onal marker, was systematically low in G93A-SOD1
mice and reached statistical signiﬁcance in the motor
cortex and brainstem (genotype factor p< 0.05,
Figure 4(b)). Over the entire study period, a trend
toward a decrease in NAA became apparent in the
symptomatic age groups. Among other metabolites
that were quantiﬁed, Tau levels globally increased in
all analysed regions (genotype factor p< 0.05, age fac-
tor< 0.05, Figure 4(c)). Furthermore, signiﬁcant diﬀer-
ences in total choline (tCho) were observed between
two groups (Figure 4(d)). In the motor cortex and
brainstem of G93A-SOD1 mice, Asc increased slightly
(Figure 3(f)), while GSH did not diﬀer from their WT
controls (Figure 4(f)).
Identification of biomarkers for early diagnosis
In order to evaluate the overall neurochemical proﬁle of
each brain region to be distinct between G93A-SOD1
and WT mice at the asymptomatic stage and thus to
provide potential early biomarkers for the ALS disease,
we performed PLS-DA for each region at P60. Hence,
Figure 5 shows that two principal components (PC1
and PC2) allow diﬀerentiating the neurochemical pro-
ﬁle of G93A-SOD1 mice from that of WT mice at age
prior to symptom onset.
Discussion
Our study showed that non-invasive short-echo
1H-MRS measurements of murine neurochemical
Table 2. Summary of physiological parameters including body weight, blood glucose and lactate (mean SDs).
Glucose (mM) Lactate (mM) Weight (g)
WT G93A-SOD1 WT G93A-SOD1a WT G93A-SOD1a,g
P60 12.3 3.6 11.6 2.7 6.5 2.3 6.3 1.2 26.0 1.7 24.1 2.9
P100 10.5 2.9 11.2 1.4 4.4 2.3 5.0 1.1 29.9 4.2 24.5 3.5***
P115 12.3 2.5 10.4 4.8 5.6 2.0 4.2 2.7 31.2 4.3 25.8 2.6*
P122 8.8 2.7 8.8 5.2 4.4 1.4 2.8 1.0 29.5 3.1 23.0 0.8*
Note: Statistical differences between groups were evaluated using two-way ANOVA and marked ‘‘g’’ for the genotype factor and
‘‘a’’ for the age factor, as superscripts. The increased number of symbols represents the levels of significant differences for the
post hoc analysis of variance comparisons between genotypes, such as ‘‘*’’: p< 0.05; ‘‘**’’: p< 0.01; ‘‘***’’: p< 0.001.
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Figure 2. Changes of major metabolites related to neurotransmission, glutamine (Gln, row a), glutamate (Glu, row b), g-amino-
butyric acid (GABA, row c), glycine (Gly, row d), the sum of glutamate and glutamine (Glx, row e) and the ratio of glutamine and
glutamate (Gln/Glu, row f) from striatum (1st column), motor cortex (2nd column) and brainstem (3rd column) of WT (solid dots)
and G93A-SOD1 (solid triangles). Statistical differences between groups were evaluated using two-way ANOVA and marked ‘‘g’’ for
the genotype factor, ‘‘a’’ for the age factor and ‘‘i’’ for the interaction. The increased number of symbols represents the levels of
significant differences for the post hoc ANOVA comparisons between genotypes, such as ‘‘*’’: p< 0.05; ‘‘**’’: p< 0.01; ‘‘***’’: p< 0.001
and ‘‘****’’: p< 0.0001. Error bars are standard errors of means (SEMs).
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Figure 3. Evolution of glucose (Glc, row a), lactate (Lac, row b), alanine (Ala, row c) and total creatine (Crþ PCr, row d), PCr/Cr
(row e) and ascorbate (Asc, row f) of striatum (1st column), motor cortex (2nd column) and brainstem (3rd column). The solid dots
were from WT mice and the solid triangles were from G93A-SOD1 mice. Statistical differences were evaluated using two-way
ANOVA and marked ‘‘g’’ for genotype factor, ‘‘a’’ for age factor and ‘‘i’’ for the interaction. The increased number of symbols
represents the levels of significant differences for the post hoc ANOVA comparisons between genotypes, such as ‘‘*’’: p< 0.05; ‘‘**’’:
p< 0.01 and ‘‘***’’: p< 0.001. Error bars are SEMs.
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Figure 4. Evolution of myo-Ins (row a), NAA (row b), Tau (row c), tCho (row d), aspartate (Asp, row e) and GSH (row f) of WT
(solid dots) and G93A-SOD1 (solid triangles) mouse striatum (1st column), motor cortex (2nd column) and brainstem (3rd column).
Statistical differences were evaluated using two-way ANOVA and marked ‘‘g’’ for genotype factor, ‘‘a’’ for age factor and ‘‘i’’ for the
interaction. The increased number of ‘‘*’’ represents the levels of significant differences, as in Figure 2.
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proﬁles of two motor neuron abundant regions (i.e.
brainstem and motor cortex) and of one brain region
speciﬁc to motor controls (i.e. striatum) are feasible at
9.4 T. We used the G93A-SOD1 mice, one animal
model with its neuropathology well-characterized and
reproducing the pathology observed in ALS patients.
This study mainly documented neurochemical changes
that occurred in the brainstem and motor cortex, two
Figure 5. Partial least squares discriminant analysis (PLS-DA) of neurochemical profiles of striatum (row a), motor cortex (row b)
and brainstem (row c) of G93A-SOD1 mice and WT mice at P60. The score plots of two components (the left column) (i.e. PC1 and
PC2) discriminate regional profiles of G93A-SOD1 mice from those of WT mice at P60. The plots of loading factors (the right column)
show the weighting contributions of each metabolite ratio in the principal components.
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brain regions that contain abundant motor neurons
and primarily aﬀected by ALS. Importantly, neuro-
chemical changes speciﬁc to G93A-SOD1 mice were
detected in both the motor cortex and brainstem
before the onset of motor symptoms. With disease pro-
gression, a number of neurochemical alterations further
evolved with the appearance of the abnormal motor
symptoms in the brainstem, motor cortex and striatum
of G93A-SOD1 mice. Overall, our study provides evi-
dence that 1H-MRS-detectable metabolic changes
occur before the onset of symptoms. The regional
neurochemical proﬁles of G93A-SOD1 mice are time-
dependent, which contribute to the characterization of
ALS progression in this animal model and may be used
to guide ALS studies in patients to improve diagnosis.
1H-MRS revealed metabolic changes in the brain
regions with abundant motor neurons
Most 1H-MRS studies performed in human ALS
patients21 have shown that NAA decreased in the
motor cortex and brainstem, which has been attributed
to neuronal cell death or dysfunction in these regions.
This is consistent with some animal models10 but
remained debatable in G93A-SOD1 mice.38,39 Indeed,
changes in the cortex appeared to be less severe and
intrinsically more diﬃcult to detect than those in the
spinal cord because of its pathology.
In our study, even in the asymptomatic G93A-SOD1
mice, several metabolic changes were observed in all
three investigated regions, including two motor
neuron abundant regions (i.e. brainstem and motor
cortex) and a brain region facilitating voluntary move-
ment (striatum). For instance, Gln was globally
elevated in all three regions (Figure 2(a)) and such an
increase became more prominent in the brainstem and
motor cortex of SOD1 mice at the mild symptomatic
stage (Table 1, Supplementary Table 2). Overall, we
hypothesise that NAA, Glu and its cycling mechanism
could indicate motor neuron dysfunction, since astro-
cytes sense neuronal activity by taking-up Glu from the
synaptic cleft, a process that is known to be dysfunc-
tional in ALS.40,41
A statistically signiﬁcant drop of NAA in the motor
cortex at P60 and, thus, such decrease might indicate a
possible trend in motor neuronal dysfunction or neur-
onal loss at this phase (Table 1, Figure 4). The NAA
reduction in the motor cortex of G93A-SOD1 mice is
within the precision of MRS measurements (i.e. 10%)
and a slight increase of Gln/Glu (Table 1, Figure 2) was
consistently detected at this stage, which indicated a
possible shift in the Gln/Glu cycle linked to neurotrans-
mission. The 1H-MR spectral proﬁles and metabolite
changes observed at this particular stage were found
diﬀerent from those at the later stage, which mimics
disease progression with more pronounced modiﬁca-
tions at the later time-points (Table 1).
While no changes were presented in either glucose or
lactate levels in the blood (Table 2), the symptomatic
changes of energy substrates (Glc and Lac) and inter-
mediates (PCr and Cr) in brain of G93A-SOD1 mice
were consistently observed (Figure 3). Such changes in
symptomatic transgenic mouse brain might likely
reﬂect impaired energy metabolism, which could pos-
sibly be related to the depletion of adenosine triphos-
phate (ATP) observed in a similar G93A-SOD1 mouse
model,42 the depletion of cortical and subcortical glu-
cose metabolism in ALS patients43 or plausible hyper-
metabolism.44 Biochemically, overexpression of SOD1
would increase the production of ATP in conversion of
both Lac and Ala towards pyruvate mainly due to its
role of binding copper and zinc ions, which was likely
to induce oxidative stress.45,46 Consequently, overex-
pression of SOD1 might partially contribute to lowered
Lac and Ala levels in G93A-SOD1 mice at both asymp-
tomatic and symptomatic stages observed here.
Mitochondrial dysfunction in the motor neurons
It has been shown that either GABAergic inhibition-
induced cortical hyperactivities47 or increased aﬃnity
of GABAA receptors
48 could lead to lowered GABA
levels, which was noticed in the motor cortex of
G93A-SOD1 mice here (Table 1, Figure 2). This
might indicate potential alterations in the GABAergic
system in the transgenic mice, similar to ALS
patients.49 Apart from these changes, Asp, one of the
key components of the malate-aspartate shuttle, was
increased in the brainstems of G93A-SOD1 mice
(Table 1, Figure 4) and might imply mitochondrial dys-
function, one factor contributing to motor neuron
degeneration in ALS.46,50,51 It also has been shown
that GABA, Asc and Tau appear to be counter-regula-
tory responses to oxidative stress (e.g. in Huntington’s
disease).52
In addition, symptomatic CrþPCr increases in the
brainstem of transgenic mice may reinforce the notion
thatmitochondrial dysfunction has occurred, further sup-
ported by the fact that the adenosine triphosphate (ATP)
depletion has been reported in G93A-SOD1 mice.42
It is of interest to note that some neurochemical
changes were present in asymptomatic G93A-SOD1
mice but evolved further with disease progression in
the striatum, a brain region that is responsible for
gating proper initiation of movements and minimally
involved in upper motor neuron dysfunction. This is
consistent with previous observations of elevated nitro-
tyrosine-related immunoreactivity (a marker of peroxy-
nitrite) in the lateral septal nucleus of G93A-SOD1
mice.7
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Excitotoxicity: An alternative evolving indicator for
motor neuron dysfunction
Over disease progression, a signiﬁcant increase in Gln
was consistently noticeable in both the brainstem
and motor cortex of G93A-SOD1 mice (Table 1,
Figure 2). The highly increased Glu contents in the
brainstem and striatum of G93A-SOD1 mice at P60
(Figure 2(b)) might be due to possible defective Glu
uptake related to reduction of astrocytic glutamate
transporter 1 (GLT-1) expression and, thus, may lead
to excitotoxicity,53 which could also explain the accu-
mulation of Gln in both striatum and motor cortex
observed by the present study (Figure 2). However, in
G93A-SOD1 mouse striatum and brainstem, Glu
tended to decrease with disease progression, reaching
levels similar to those in the controls at P115 and
dropped even further at P122 (Figure 2(b)). In the
motor cortex of transgenic mice, Glu decreased
while Gln on the other hand appeared to increase.
Consequently, a signiﬁcant 40% increase of cortical
Gln/Glu ratio (Figure 2) was found when comparing
to that of WT mice. This was consistent with the obser-
vations in the G93A-SOD1 mice at P60 from the same
brain region and indicated possible neuronal dysfunc-
tion or loss.54 The similar pattern of the increased Gln/
Glu ratios was observed in both the striatum and brain-
stem of the G93A-SOD1 mice as well at this stage
(Table 1, Figure 2(f), Supplementary Table 2). While
overexpressing hSOD1 has minimal eﬀect on liver,55
such cerebral accumulation of Gln accompanied by
changes in Glu (Table 1, Figure 2) may not be due to
ineﬃcient ammonia detoxiﬁcation by the liver.56 Thus,
these Gln/Glu changes are consistent with excitotoxi-
city and observations in ALS,57 other neurodegenera-
tive diseases and transient ischemia25,58 and could to
some extent explain motor neuron degeneration in
ALS.40
The elevated Glx (GluþGln) levels in G93A-SOD1
mice brainstems observed in this study is similar to a
previous study,20 with the exception that Gln and Glu
evolve distinctly in the three investigated brain regions
(Figure 2). Glx increased in the striatum of SOD1 mice
but not in the motor cortex. This implies that diﬀeren-
tiating Gln and Glu in speciﬁc brain regions using
short-echo 1H-MRS at high magnetic ﬁelds would
reveal early changes relating to excitotoxicity that
might remain obscure considering Glx alone.14,20,49,59
Multiple types of brain cells might play roles in motor
neuron dysfunction
In addition to excitotoxicity, gliosis has been suggested
as a potential indicator for neuronal damage in neuro-
degenerative diseases, such as ALS. Numerous
immunohistochemistry studies of ALS animal models
and patients indicated possible astrogliosis and micro-
gliosis.11,58,60–62 A G93A-SOD1 mouse model with
a nearly identical lifespan7 as ours presented with
astrogliosis as early as asymptomatic but preceding
microgliosis, which signiﬁcantly increased only when
the G93A-SOD1 mice were at the end-stage. In our
study, myo-Ins in the G93A-SOD1 mouse brainstem
increased slightly at P100 and evolved further at P115
(Figure 4), which are consistent with the observed
microgliosis in one ALS murine model with the identi-
cal lifespan.7 Alternatively, microglia activations might
not be substantial enough7 for causing any myo-Ins
elevations in the motor cortex and striatum of G93A-
SOD1 mice (Figure 4(a)), and support the ﬁndings that
proliferating microglia might not be the key contribu-
tors to ALS disease progression.63 Thus, the slightly
lowered NAA in the motor cortex of G93A-SOD1
mice, at least before P122, might indicate neuronal dys-
function rather than neuronal loss.7
Since cerebral Gln is only synthesised in astrocytes,64
the elevated trends of Gln over three regions of the
brain are consistent with an involvement of astrocytes
in the G93A-SOD1 mouse brain (Figure 2, Table 1),
along with additional changes in Glu and GABA.
Furthermore, we have not detected any reduction in
either Asc (Figure 3(f)) or GSH (Figure 4(f)) in the
motor neurons abundant brain regions of transgenic
mice. Instead, the elevation of Asc concentration was
observed in the motor cortex of G93A-SOD1 mice.
Since Asc can be synthesised in mice65 while GSH did
not reduce, such Asc increase may not attribute to any
dietary changes. This could be likely associated with
oxidative stress and linked to a possible abnormal
ascorbic acid ﬂux between astrocytes and neurons
after Glu stimulation.66,67 Taken together, in vivo evi-
dence supports the notion that multiple brain cells are
involved in disease progression in the G93A-SOD1
mouse brain, even prior to symptom onset.
It is interesting to note that among three investigated
brain regions of the WT controls at P60 (Figure 1(b)),
brainstem exhibited the lowest anti-oxidant contents,
e.g. Asc and GSH (two-way ANOVA analysis on
region and metabolite factors, brainstem vs. stri-
atum: region factor p-value¼ 0.0027 and metabolite
factor p-value¼ 0.015; brainstem vs. motor cortex:
region factor p-value¼ 0.0009 and metabolite factor
p-value¼ 0.07). This may partially explain why the
brainstem of G93A-SOD1 mice is more susceptible to
oxidative stress and exhibited a slightly diﬀerent pat-
tern of neurochemical alterations when comparing to
another motor neuron abundant brain region with
more anti-oxidants reservoirs, i.e. motor cortex,68 and
most likely became one of the most profoundly aﬀected
brain regions (Figures 2 to 4, Supplementary Table 2).
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Identification of early biomarkers in the
G93A-SOD1 mice
The neurochemical changes observed in the present
study are consistent with the underlying cellular
responses of ALS that evolve with disease progression.
Despite the complex disease progression, metabolic
changes occurred for a number of metabolites, such
as Lac, Gln, Glu, NAA and Tau (Figures 2 to 4,
Supplementary Table 2), in the striatum, motor cortex
and brainstem of G93A-SOD1 mice. By plotting most
of the metabolites over the entire periods, both onset
times and region-speciﬁc amplitudes of those metabolic
changes were noticeably associated with the ALS dis-
ease progression (Figures 2 to 4), which need to be
explored further in human ALS. The multiple changes
observed at asymptomatic and symptomatic ages are of
great interest as they proﬁle high magnetic ﬁeld short-
echo spectroscopy as a potential diagnostic tool in
ALS.
The estimation of early disease biomarkers was pro-
posed to adapt the ability of the PLS-DA on the large
number of metabolites. With signiﬁcant changes in
selected metabolites (Glu, GABA, Lac, NAA and
Asc (as listed in Table 1)), a clear separation between
mice overexpressed with G93A-SOD1 and their
respective controls is shown in three brain regions at
P60, the asymptomatic age (Figure 5). When examining
the PLS-DA loading factors, other metabolites were
noticed to be major contributors in the separation of
both G93A-SOD1 mice and WT controls (Figure 5).
For instance, Lac was noted to be one major contribu-
tor to PC1 in all three regions, and Glc was the other
major contributor to PC2 in all three regions (Figure 5).
Such results reinforce the notion that overexpression of
SOD1 alters energy metabolism and is in line with low-
ered glycolysis, which was consistent with the observa-
tions in lowered Lac and highly elevated Glc at its late
stage (Figure 3), and thereafter were conﬁrmed by our
preliminary positron-emission tomography (PET) ima-
ging results assessed towards the end-stage of G93A-
SOD1 mice (Supplementary Figure 1).
Our results demonstrate that short-echo 1H-MRS at
9.4T allows non-invasive assessment of neurochemical
evolutions of the striatum, motor cortex and brainstem
of one ALS animal model and provides metabolic bio-
markers speciﬁc to mice overexpressing G93A-SOD1.
Most recently, the development of short-echo 1H-MRS
at high magnetic ﬁelds for humans69 could further
determine whether the spectroscopic signature observed
in this experiment is relevant for ALS patients. Hence,
besides providing in vivo insights on ALS pathogenesis,
short-echo 1H-MRS has the potential for important
applications towards to diagnosis and prognosis of
ALS patients.
Conclusion
We conclude that 1H-MRS allows researchers to longi-
tudinally study murine G93A-SOD1 models mimicking
human ALS disease, providing region- and time-
speciﬁc neurochemical proﬁles and alterations in the
striatum, brainstem and motor cortex. Such metabolic
alterations preceding symptom-onset in the ALS mouse
models can yield additional insights into disease pro-
gression, identify early diagnosis biomarkers and ultim-
ately aid in seeking targets for therapy.
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